[
  {
    "ts": null,
    "headline": "Earnings Preview: Kenvue (KVUE) Q3 Earnings Expected to Decline",
    "summary": "Kenvue (KVUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=e8e49a814c6483c989715de85352139457abcf3a82a09145508a1bfb6588da1f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761832835,
      "headline": "Earnings Preview: Kenvue (KVUE) Q3 Earnings Expected to Decline",
      "id": 137269615,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "KVUE",
      "source": "Yahoo",
      "summary": "Kenvue (KVUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=e8e49a814c6483c989715de85352139457abcf3a82a09145508a1bfb6588da1f"
    }
  },
  {
    "ts": null,
    "headline": "Jefferies Lowers Kenvue (KVUE) PT to $23, Cites Macroeconomic Headwinds for Consumer Health",
    "summary": "Kenvue Inc. (NYSE:KVUE) is one of the best up and coming stocks to buy right now. On October 27, Jefferies analyst Keith Devas lowered the firm’s price target on Kenvue to $23 from $25 and maintained a Buy rating on the shares, as the current macroeconomic challenges are impacting consumer health stocks more than the […]",
    "url": "https://finnhub.io/api/news?id=9783c2e4cf4f59a2a7c3b2151ad185c3646bdfd4e06428610bb1dc90b0111116",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761832624,
      "headline": "Jefferies Lowers Kenvue (KVUE) PT to $23, Cites Macroeconomic Headwinds for Consumer Health",
      "id": 137267039,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "KVUE",
      "source": "Yahoo",
      "summary": "Kenvue Inc. (NYSE:KVUE) is one of the best up and coming stocks to buy right now. On October 27, Jefferies analyst Keith Devas lowered the firm’s price target on Kenvue to $23 from $25 and maintained a Buy rating on the shares, as the current macroeconomic challenges are impacting consumer health stocks more than the […]",
      "url": "https://finnhub.io/api/news?id=9783c2e4cf4f59a2a7c3b2151ad185c3646bdfd4e06428610bb1dc90b0111116"
    }
  },
  {
    "ts": null,
    "headline": "Kenvue: Remains A Sell Until The Dividend Is Cut",
    "summary": "Kenvue faces declining sales and high debt post-spin-off. Read why a dividend cut may be imminent and why KVUE stock is a Sell.",
    "url": "https://finnhub.io/api/news?id=0a1000fd25b7ea66077a244ea0aef90ce5e587e3081d5fcf563b3836fe1cdae2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761788261,
      "headline": "Kenvue: Remains A Sell Until The Dividend Is Cut",
      "id": 137262962,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/494180077/image_494180077.jpg?io=getty-c-w1536",
      "related": "KVUE",
      "source": "SeekingAlpha",
      "summary": "Kenvue faces declining sales and high debt post-spin-off. Read why a dividend cut may be imminent and why KVUE stock is a Sell.",
      "url": "https://finnhub.io/api/news?id=0a1000fd25b7ea66077a244ea0aef90ce5e587e3081d5fcf563b3836fe1cdae2"
    }
  }
]